Adam L Halberstadt1,2, Muhammad Chatha1, Stephen J Chapman3, Simon D Brandt4. 1. 1 Department of Psychiatry, University of California San Diego, La Jolla, CA, USA. 2. 2 Research Service, VA San Diego Healthcare System, San Diego, CA, USA. 3. 3 Isomer Design, Toronto, ON, Canada. 4. 4 School of Pharmacy and Biomolecular Sciences, Liverpool John Moores University, Byrom Street, Liverpool, UK.
Abstract
BACKGROUND: In recent years, there has been increasing scientific interest in the effects and pharmacology of serotonergic hallucinogens. While a large amount of experimental work has been conducted to characterize the behavioral response to hallucinogens in rodents, there has been little systematic investigation of mescaline and its analogs. The hallucinogenic potency of mescaline is increased by α-methylation and by homologation of the 4-methoxy group but it not clear whether these structural modifications have similar effects on the activity of mescaline in rodent models. METHODS: In the present study, the head twitch response (HTR), a 5-HT2A receptor-mediated behavior induced by serotonergic hallucinogens, was used to assess the effects of mescaline and several analogs in C57BL/6J mice. HTR experiments were conducted with mescaline, escaline (4-ethoxy-3,5-dimethoxyphenylethylamine) and proscaline (3,5-dimethoxy-4-propoxyphenylethylamine), their α-methyl homologs TMA (3,4,5-trimethoxyamphetamine), 3C-E (4-ethoxy-3,5-dimethoxyamphetamine) and 3C-P (3,5-dimethoxy-4-propoxyamphetamine), and the 2,4,5-substituted regioisomers TMA-2 (2,4,5-trimethoxyamphetamine), MEM (4-ethoxy-2,5-dimethoxyamphetamine) and MPM (2,5-dimethoxy-4-propoxyamphetamine). RESULTS: TMA induced the HTR and was twice as potent as mescaline. For both mescaline and TMA, replacing the 4-methoxy substituent with an ethoxy or propoxy group increased potency in the HTR assay. By contrast, although TMA-2 also induced the HTR with twice the potency of mescaline, potency was not altered by homologation of the 4-alkoxy group in TMA-2. CONCLUSIONS: The potency relationships for these compounds in mice closely parallel the human hallucinogenic data. These findings are consistent with evidence that 2,4,5- and 3,4,5-substituted phenylalkylamine hallucinogens exhibit distinct structure-activity relationships. These results provide additional evidence that the HTR assay can be used to investigate the structure-activity relationships of serotonergic hallucinogens.
BACKGROUND: In recent years, there has been increasing scientific interest in the effects and pharmacology of serotonergic hallucinogens. While a large amount of experimental work has been conducted to characterize the behavioral response to hallucinogens in rodents, there has been little systematic investigation of mescaline and its analogs. The hallucinogenic potency of mescaline is increased by α-methylation and by homologation of the 4-methoxy group but it not clear whether these structural modifications have similar effects on the activity of mescaline in rodent models. METHODS: In the present study, the head twitch response (HTR), a 5-HT2A receptor-mediated behavior induced by serotonergic hallucinogens, was used to assess the effects of mescaline and several analogs in C57BL/6J mice. HTR experiments were conducted with mescaline, escaline (4-ethoxy-3,5-dimethoxyphenylethylamine) and proscaline (3,5-dimethoxy-4-propoxyphenylethylamine), their α-methyl homologs TMA (3,4,5-trimethoxyamphetamine), 3C-E (4-ethoxy-3,5-dimethoxyamphetamine) and 3C-P (3,5-dimethoxy-4-propoxyamphetamine), and the 2,4,5-substituted regioisomers TMA-2 (2,4,5-trimethoxyamphetamine), MEM (4-ethoxy-2,5-dimethoxyamphetamine) and MPM (2,5-dimethoxy-4-propoxyamphetamine). RESULTS:TMA induced the HTR and was twice as potent as mescaline. For both mescaline and TMA, replacing the 4-methoxy substituent with an ethoxy or propoxy group increased potency in the HTR assay. By contrast, although TMA-2 also induced the HTR with twice the potency of mescaline, potency was not altered by homologation of the 4-alkoxy group in TMA-2. CONCLUSIONS: The potency relationships for these compounds in mice closely parallel the human hallucinogenic data. These findings are consistent with evidence that 2,4,5- and 3,4,5-substituted phenylalkylamine hallucinogens exhibit distinct structure-activity relationships. These results provide additional evidence that the HTR assay can be used to investigate the structure-activity relationships of serotonergic hallucinogens.
Entities:
Keywords:
Psychedelic; animal model; head shake; phenylethylamine; phenylisopropylamine
Authors: A P Monte; S R Waldman; D Marona-Lewicka; D B Wainscott; D L Nelson; E Sanders-Bush; D E Nichols Journal: J Med Chem Date: 1997-09-12 Impact factor: 7.446
Authors: Anders A Jensen; John D McCorvy; Sebastian Leth-Petersen; Christoffer Bundgaard; Gudrun Liebscher; Terry P Kenakin; Hans Bräuner-Osborne; Jan Kehler; Jesper Langgaard Kristensen Journal: J Pharmacol Exp Ther Date: 2017-03-30 Impact factor: 4.030
Authors: William E Fantegrossi; Chad J Reissig; Elyse B Katz; Haley L Yarosh; Kenner C Rice; Jerrold C Winter Journal: Pharmacol Biochem Behav Date: 2007-09-14 Impact factor: 3.533
Authors: Clinton E Canal; Uade B Olaghere da Silva; Paul J Gresch; Erin E Watt; Elaine Sanders-Bush; David C Airey Journal: Psychopharmacology (Berl) Date: 2010-02-19 Impact factor: 4.530
Authors: David E Nichols; M Flori Sassano; Adam L Halberstadt; Landon M Klein; Simon D Brandt; Simon P Elliott; Wolfgang J Fiedler Journal: ACS Chem Neurosci Date: 2015-01-21 Impact factor: 4.418
Authors: Roland R Griffiths; Matthew W Johnson; Michael A Carducci; Annie Umbricht; William A Richards; Brian D Richards; Mary P Cosimano; Margaret A Klinedinst Journal: J Psychopharmacol Date: 2016-12 Impact factor: 4.153
Authors: Simon D Brandt; Pierce V Kavanagh; Folker Westphal; Alexander Stratford; Simon P Elliott; Geraldine Dowling; Jason Wallach; Adam L Halberstadt Journal: Drug Test Anal Date: 2019-06-18 Impact factor: 3.345
Authors: Adam L Halberstadt; Muhammad Chatha; Adam K Klein; Jason Wallach; Simon D Brandt Journal: Neuropharmacology Date: 2020-01-07 Impact factor: 5.273
Authors: Karolina E Kolaczynska; Dino Luethi; Daniel Trachsel; Marius C Hoener; Matthias E Liechti Journal: Front Pharmacol Date: 2019-11-28 Impact factor: 5.810
Authors: Karolina E Kolaczynska; Dino Luethi; Daniel Trachsel; Marius C Hoener; Matthias E Liechti Journal: Front Pharmacol Date: 2022-02-09 Impact factor: 5.810
Authors: Adam L Halberstadt; Muhammad Chatha; Adam K Klein; John D McCorvy; Markus R Meyer; Lea Wagmann; Alexander Stratford; Simon D Brandt Journal: Neuropharmacology Date: 2019-11-19 Impact factor: 5.273